Improved wet weight absorption with apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC)

Rationale: SBS-IF is a severe organ failure condition with life-long PS dependence. Glucagon-like peptide-2 (GLP-2) stimulates intestinal adaptation resulting in increased absorptive capacity of nutrients and fluids. Apraglutide (APRA) is a novel long-acting synthetic GLP-2 analog in development for SBS-IF. We performed a pre-defined interim analysis of a phase 2 study in SBS-IF-CiC to investigate the safety and efficacy of 4W APRA treatment based on metabolic balance studies (MBS).

Source: Clinical Nutrition ESPEN - December 1, 2023 Category: Nutrition Authors: A. Verbiest, M.K. Hvistendahl, F. Bolognani, C. Li, O. Khwaja, F. Joly, P.B. Jeppesen, T. Vanuytsel Source Type: research